Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that the United States Patent and Trade Mark Office (USPTO) has granted a key patent, US Patent 7,399,632, through to at least the year 2019.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB; USOTC: MBLTY), today announced highly significant preclinical trial results of the adult stem cell technology platform for the treatment of eye diseases associated with abnormal blood vessels. These diseases include diabetic retinopathy and age-related macular degeneration (AMD), the leading causes of blindness in the western world.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced that it will add the treatment of bacterial vaginosis (BV) to the development program for its vaginal microbicide VivaGel(R).
HELICON GROUP LIMITED (ASX:HCG) today announced that the Chinese State Food and Drug Administration (SFDA) has granted approval for the skin regeneration concept and device, ReCell(R).
Mesoblast Limited's (ASX:MSB; USOTC:MBLTY) "Off the Shelf" adult stem cells heal bodies without rejection or ethical issues, now about 3 years from commercialisation and trading near its lows.
According to the June edition of Bioshares, Mesoblast Limited (ASX:MSB)(USOTC:MBLTY)(PINK:MEOBF) has made exceptionally good progress with its adult stem cell therapy in several applications.
Helicon Group (ASX:HCG) wishes to inform the market of the release of a third party research report, compiled by Money Cat Consulting, which focuses on the company's core competencies, business model and product acquisitions.
